Skip to main content

Animations

MJFF Publications

5011 - 5020 of 9038 Results
Title
Year
  • Year
  • 2024
  • 2024
  • 2024
  • 2024
  • 2024
  • 2020
  • 2021
  • 2024
  • 2024
  • 2024
  • Summary Details
    OPEN
    Title: Unfolded protein response markers Grp78 and eIF2alpha are upregulated with increasing alpha‐synuclein levels in Lewy body disease
    Journal Name: Neuropathology and Applied Neurobiology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1111/nan.12999
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants
    Journal Name: CPT: Pharmacometrics & Systems Pharmacology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/psp4.13112
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Staging of progressive supranuclear palsy-Richardson syndrome using MRI brain charts for the human lifespan
    Journal Name: Brain Communications
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1093/braincomms/fcae055
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Perspective Strategies for Interventions in Parkinsonism: Remedying the Neglected Role of TPPP
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells13040338
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Evaluation of ATN PD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000208033
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2020.4725
    Citation Count: 146
  • Summary Details
    OPEN
    Title: Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2021.4222
    Citation Count: 99
  • Summary Details
    OPEN
    Title: Advancing precision medicine therapeutics for Parkinson’s utilizing a shared quantitative systems pharmacology model and framework
    Journal Name: Frontiers in Systems Biology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fsysb.2024.1351555
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Associations between Sleep Disorders and Impulsive-Compulsive Behaviors in Parkinson’s Disease: A Prospective Cohort Study
    Journal Name: Neuroepidemiology
    Publisher: S. Karger AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1159/000536555
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Acceptability of digital health technologies in early Parkinson's disease: lessons from WATCH-PD
    Journal Name: Frontiers in Digital Health
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fdgth.2024.1435693
    Citation Count: 6
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.